A 69-year-old man with indolent non-Hodgkin lymphoma presented with intermittent high fevers, severe chills, night sweats, and bilateral leg edema. He had begun immunochemotherapy (R-CVP, including rituximab) in April 2024 and was admitted on July 23, 2024, with nonneutropenic fever. Basic investigations—chest radiograph, urine analysis, and blood cultures—were unrevealing, yet laboratory testing showed leukocytosis and an elevated C-reactive protein. Clinicians initiated empirical cefuroxime; fever persisted beyond five days, prompting further evaluation including PET imaging that revealed no occult infectious focus but confirmed a good lymphoma treatment response. The patient experienced symptomatic relief between fever episodes, creating a pattern of episodic illness that recurred during subsequent lymphoma therapy cycles.
The clinical course involved repeated hospital readmissions. On November 19, 2024, he returned with a spike to 40.3°C and again received cefuroxime without clinical improvement. During these febrile episodes the patient developed systemic inflammatory response syndrome with hypotension and tachycardia, requiring fluid resuscitation. Nonsteroidal antiinflammatory drugs were later used and appeared to blunt febrile peaks transiently. A third admission on December 31, 2024, showed a distinctive cyclical fever pattern of approximately 48 hours between peaks, with episodes beginning in chills and escalating to temperatures above 41°C.
Repeated standard cultures and routine imaging failed to identify a cause. The diagnostic breakthrough occurred after bone marrow biopsy appeared reactive but not malignant; clinicians pursued molecular testing. Broad-range PCR targeting the 16S V3–V4 region followed by sequencing detected DNA matching Neoehrlichia mikurensis. Confirmation came from a species-specific PCR performed at the National Institute for Public Health and the Environment in the Netherlands. The patient himself did not report a definitive tick bite, although he had recently hiked in a national park; that exposure provided a plausible source for a tickborne pathogen. The authors noted that detection required access to targeted molecular assays or broad-range 16S sequencing, techniques available only in specialized laboratories.
On January 7, 2025, clinicians started oral doxycycline 100 mg twice daily for a 3-week course. Fever and leg edema subsided within days of initiating therapy. Subsequent blood PCR testing at 3 months and again at 6 months after treatment completion returned negative for N. mikurensis DNA. The authors report that recommended treatment for clinically relevant infection is doxycycline 100 mg twice daily for 2–3 weeks and that shorter or lower-dose regimens may be associated with recurrence, especially in immunocompromised patients.
The report places this case within a growing body of evidence that Neoehrlichia mikurensis is an emerging intracellular bacterium in Europe and Asia. The pathogen is transmitted by ticks, particularly Ixodes ricinus, and has been detected at substantial prevalence in western European tick populations. The literature the authors cite includes cohort data showing a notable proportion of clinically detected infections in patients receiving immunosuppressive regimens that include B-cell–depleting agents such as rituximab. Clinical manifestations range from mild febrile illness to severe presentations including vasculitis and thromboembolic events; in this case the presentation was dominated by cyclical fever and systemic inflammatory responses.
Detection of N. mikurensis relies on PCR-based methods—either broad-range 16S rRNA sequencing or species-specific assays—techniques that are not widely available in routine hospital laboratories. This limitation can delay diagnosis and lead to repeated empirical antibiotic trials that do not target the organism. The authors emphasize that increasing use of immunosuppressive therapies, together with frequent human exposure to I. ricinus ticks, may raise the incidence of clinically relevant infections. They call for prospective studies of patients who develop fever after tick exposure to better define incidence, optimize diagnostic pathways, and establish evidence-based treatment durations for immunocompromised populations. The article ends by noting these gaps as specific unanswered clinical questions warranting systematic investigation rather than offering a broad or philosophical summary.